Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Working Capital Changes (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Other Working Capital Changes for 4 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 63.91% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.5 million, a 171.86% decrease, with the full-year FY2025 number at -$5.5 million, down 171.86% from a year prior.
  • Other Working Capital Changes was $2.1 million for Q4 2025 at Phathom Pharmaceuticals, up from -$1.4 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $5.9 million in Q4 2024 to a low of -$7.8 million in Q1 2025.
  • A 4-year average of $755375.0 and a median of $909000.0 in 2023 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: skyrocketed 2218.11% in 2024, then plummeted 1647.2% in 2025.
  • Phathom Pharmaceuticals' Other Working Capital Changes stood at $4.2 million in 2022, then tumbled by 93.88% to $254000.0 in 2023, then surged by 2218.11% to $5.9 million in 2024, then crashed by 63.91% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Other Working Capital Changes are $2.1 million (Q4 2025), -$1.4 million (Q3 2025), and $1.6 million (Q2 2025).